LEVAQUIN® Receives FDA Approval for Treatment of Chronic Bacterial Prostatitis
Raritan, NJ (May 29, 2003) - The U.S. Food and Drug Administration (FDA) has approved LEVAQUIN® (levofloxacin) Tablets/Injection and LEVAQUIN® (levofloxacin in five percent dextrose) Injection for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis or Staphylococcus epidermidis. Chronic bacterial prostatitis is a recurrent or persistent infection of the prostate gland and the number one reason men under the age of 50 visit urologists. With this indication, LEVAQUIN® becomes the only once-daily fluoroquinolone indicated to treat chronic bacterial prostatitis.
Content on UroToday and UroToday International Journal is copyrighted and can be used for personal, noncommercial use only. You can order presentation-ready copies for distribution to your colleagues, clients or customers by emailing UroToday at commercialreprints@urotoday.com. Request a reprint quote of this article now, please include the title of the article and number or copies requested.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 Digital Science Press, Inc ® All Rights Reserved |
